Articles by Keyword for

  According to researchers at the University of California Medical Center, and published in the March issue of Internal Medicine, screening for breast cancer every two years is preferrable to yearly screens when doing mammograms. This was based on a study of 900,000 women. It appears that this applies to women from the age of 50-94. Mammograms picked...

Dr. Len and Nurse Vicki review factors that increase risk for and methods of screening for breast cancer. They cover mammograms, ultrasounds, manual examination, MRIs, and breast thermography.    

  Breast thermograpy is the best screening technology in medicine for breast cancer in pre-menopausal women. There is no radiation and there are few false positive and negative results. Mammography is compared.        

  The FDA published information in Journal Watch in June of 2011 that is packed with presumptive and incorrect information about breast thermography and they have to know it! Breast thermography was approved in 1982 as an adjunct to mammography to evaluate for breast cancer. In 2004 the FDA rejected breast thermography as a stand alone test for breast...

A novel new test is described that has not yet come into clinical practice that takes up a radioactive dye that puts out gamma rays. It is accurate but obviously has dangers related to radiation exposure. This is a potential way of screening women with dense breasts (fibrocystic breasts). Mammograms are not either an accurate or sensitive test in women with...

Only about 10% of cancers are caused by genetic factors such as the BRACA gene defect. Factors increasing the risk for breast cancer such as estrogen, environmental factors, unhealthy fats, alcohol, low fiber diet, smoking, birth control pills, and HRT, are reviewed. Methylation and related factors such as B12, folic acid, and B6 influence DNA repair and...

Women with dense breasts from fibrocystic breast disease have up to a six time increased risk for developing breast cancer that is especially aggressive and often involves women under the age of 50. There is no accurate and affordable mainstream test to differentiate fibrocystic disease from breasts cancer. Yet digital mammograms are are relied upon to screen...